Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 16 of 16

TitleReference numberPublishedLast updated
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessmentHTG756
Cardiovascular risk assessment and lipid modificationQS100
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Pulsed-field ablation for atrial fibrillationIPG806
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
One-piece closed bags for colostomies: late-stage assessmentHTG754
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessmentHTG753
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Dapagliflozin for treating chronic kidney diseaseTA1075

Results per page

  1. 10
  2. 25
  3. 50
  4. All